Pantoprazol Cinfa (Pantoprazole)

Pantoprazole works by selectively and irreversibly inhibiting the gastric H+/K+‑ATPase (proton pump) in the parietal cells of the stomach. This blocks the final step of acid secretion, resulting in a sustained increase in gastric pH and a reduction in the amount of acid that reaches the oesophagus and duodenum.

The prescribed dose of Pantoprazol Cinfa is determined by the treating physician based on the specific indication, severity of disease and patient characteristics. Dosage regimens are individualized and should follow the prescriber’s instructions and local labeling requirements.

Pantoprazole is classified as pregnancy category B in many regions, indicating no proven risk in animal studies but limited human data. It should be used during pregnancy or lactation only if clearly needed and after a risk‑benefit assessment by the healthcare professional.

To place an order, submit an enquiry on the Pantoprazol Cinfa product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Pantoprazole belongs to the proton pump inhibitor class, which provides more potent and longer‑lasting acid suppression than H2‑receptor antagonists such as ranitidine. Compared with other PPIs, pantoprazole has a lower potential for CYP‑mediated drug interactions, making it a preferred option for patients on multiple medications.

Pantoprazol Cinfa should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and avoid exposure to extreme temperatures or humidity.

The product is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious adverse events, although rare, include severe allergic reactions (anaphylaxis), Clostridioides difficile‑associated colitis, low magnesium levels, acute interstitial nephritis and liver enzyme elevations. Patients should be advised to seek immediate medical attention if they experience symptoms such as rash, persistent diarrhea, muscle weakness or jaundice.

Pantoprazol Cinfa is contraindicated in patients with known hypersensitivity to pantoprazole or any other component of the formulation. Caution is also advised for individuals with severe hepatic impairment, those on certain interacting medications, and patients who are pregnant or breastfeeding unless the benefit outweighs the risk.